Gastritis classification: Difference between revisions
No edit summary |
|||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Gastritis}} | {{Gastritis}} | ||
{{CMG}}; {{AE}} {{ARK}}}} | {{CMG}}; {{AE}} {{ARK}}<nowiki>}}</nowiki> | ||
==Overview== | ==Overview== | ||
The Updated Sydney System establishes the classification and grading of gastritis which underlines the significance of combining topographical, morphological, and etiological information to help arrive at clinical diagnosis. In clinical practice, Gastritis staging is done using the OLGA (Operative Link on Gastritis Assessment) staging system for reporting gastric histology. Gastritis staging combines the atrophy score which is determined by biopsy and the atrophy topography which is determined by directed biopsy mapping. | The Updated Sydney System establishes the classification and grading of gastritis which underlines the significance of combining topographical, morphological, and etiological information to help arrive at clinical diagnosis. In clinical practice, Gastritis staging is done using the OLGA (Operative Link on Gastritis Assessment) staging system for reporting gastric histology. Gastritis staging combines the [[atrophy]] score which is determined by biopsy and the [[atrophy]] topography which is determined by directed [[biopsy]] mapping. | ||
==Classification== | ==Classification== | ||
*The Updated Sydney System establishes the classification and grading of gastritis which underlines the significance of combining topographical, morphological, and etiological information to help arrive at clinical diagnosis. <ref name="pmid8827022">{{cite journal| author=Dixon MF, Genta RM, Yardley JH, Correa P| title=Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. | journal=Am J Surg Pathol | year= 1996 | volume= 20 | issue= 10 | pages= 1161-81 | pmid=8827022 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8827022 }} </ref> | *The Updated Sydney System establishes the classification and grading of gastritis which underlines the significance of combining topographical, morphological, and etiological information to help arrive at clinical diagnosis. <ref name="pmid8827022">{{cite journal| author=Dixon MF, Genta RM, Yardley JH, Correa P| title=Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. | journal=Am J Surg Pathol | year= 1996 | volume= 20 | issue= 10 | pages= 1161-81 | pmid=8827022 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8827022 }} </ref> | ||
<br/> | <br /> | ||
{| | {| | ||
!colspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" + |'''Classification and grading of Gastritis: Updated Sydney System''' | ! colspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" + |'''Classification and grading of Gastritis: Updated Sydney System''' | ||
|- | |- | ||
!colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + | Type of Gastritis | ! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + | Type of Gastritis | ||
!style="background:#4479BA; color: #FFFFFF;" align="center" + |Etiology | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Etiology | ||
!style="background:#4479BA; color: #FFFFFF;" align="center" + |Gastritis synonyms | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Gastritis synonyms | ||
|- | |- | ||
|colspan="2" style="background:#DCDCDC;" align="center" + | Non-atrophic | | colspan="2" style="background:#DCDCDC;" align="center" + | Non-atrophic | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Helicobacter pylori | *Helicobacter pylori | ||
*Other factors | *Other factors | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Superficial | *Superficial | ||
*Diffuse antral gastritis (DAG) | *Diffuse antral gastritis (DAG) | ||
Line 28: | Line 28: | ||
*Type B* | *Type B* | ||
|- | |- | ||
|rowspan="4" style="background:#DCDCDC;" align="center" + |Atrophic | | rowspan="4" style="background:#DCDCDC;" align="center" + |Atrophic | ||
| style="background:#DCDCDC;" align="center" + |Autoimmune | | style="background:#DCDCDC;" align="center" + |Autoimmune | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Autoimmunity | *Autoimmunity | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Type A* | *Type A* | ||
*Diffuse corporal | *Diffuse corporal | ||
*Pernicious anemia-associated | *Pernicious anemia-associated | ||
|- | |- | ||
|rowspan="3" style="background:#DCDCDC;" align="center" + |Multifocal atrophic | | rowspan="3" style="background:#DCDCDC;" align="center" + |Multifocal atrophic | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Helicobacter pylori | *Helicobacter pylori | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Type B*, type AB* | *Type B*, type AB* | ||
|- | |- | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Dietary | *Dietary | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Environmental | *Environmental | ||
|- | |- | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Environmental factors | *Environmental factors | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Metaplastic | *Metaplastic | ||
|- | |- | ||
|rowspan="21" style="background:#DCDCDC;" align="center" + | Special forms | | rowspan="21" style="background:#DCDCDC;" align="center" + | Special forms | ||
|rowspan="4" style="background:#DCDCDC;" align="center" + | Chemical | | rowspan="4" style="background:#DCDCDC;" align="center" + | Chemical | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Chemical irritation | *Chemical irritation | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Reactive | *Reactive | ||
|- | |- | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Bile | *Bile | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Reflux | *Reflux | ||
|- | |- | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*NSAIDs | *NSAIDs | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*NSAID | *NSAID | ||
|- | |- | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Other agents | *Other agents | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Type C | *Type C | ||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + |Radiation | | style="background:#DCDCDC;" align="center" + |Radiation | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Radiation injury | *Radiation injury | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
|- | |- | ||
| rowspan="4" style="background:#DCDCDC;" align="center" + |Lymphocytic | | rowspan="4" style="background:#DCDCDC;" align="center" + |Lymphocytic | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Idiopathic? Immune mechanisms | *Idiopathic? Immune mechanisms | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Varioliform (endoscopic) | *Varioliform (endoscopic) | ||
|- | |- | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Gluten | *Gluten | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Celiac disease-associated | *Celiac disease-associated | ||
|- | |- | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Drug (ticlopidine) | *Drug (ticlopidine) | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
|- | |- | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*H. pylori | *H. pylori | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
|- | |- | ||
| rowspan="5" style="background:#DCDCDC;" align="center" + |Noninfectious granulomatous | | rowspan="5" style="background:#DCDCDC;" align="center" + |Noninfectious granulomatous | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Crohn's disease | *Crohn's disease | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
|- | |- | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Sarcoidosis | *Sarcoidosis | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
|- | |- | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Granulomatosis with polyangiitis and other vasculitides | *Granulomatosis with polyangiitis and other vasculitides | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
|- | |- | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Foreign substances | *Foreign substances | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
|- | |- | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Idiopathic | *Idiopathic | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Isolated granulomatous | *Isolated granulomatous | ||
|- | |- | ||
| rowspan="2" style="background:#DCDCDC;" align="center" + |Eosinophilic | | rowspan="2" style="background:#DCDCDC;" align="center" + |Eosinophilic | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Food sensitivity | *Food sensitivity | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Allergic | *Allergic | ||
|- | |- | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Other allergies | *Other allergies | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
|- | |- | ||
| rowspan="2" style="background:#DCDCDC;" align="center" + |Other infectious gastritides | | rowspan="2" style="background:#DCDCDC;" align="center" + |Other infectious gastritides | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Bacteria (other than H. pylori) | *Bacteria (other than H. pylori) | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Phlegmonous | *Phlegmonous | ||
|- | |- | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Viruses | *Viruses | ||
*Fungi | *Fungi | ||
*Parasites | *Parasites | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
|} | |} | ||
<br/> | <br /> | ||
<br/> | <br /> | ||
*In clinical practice, Gastritis staging is done using the OLGA (Operative Link on Gastritis Assessment) staging system for reporting gastric histology. Gastritis staging combines the atrophy score which is determined by biopsy and the atrophy topography which is determined by directed biopsy mapping. <ref name="pmid17142647">{{cite journal| author=Rugge M, Meggio A, Pennelli G, Piscioli F, Giacomelli L, De Pretis G et al.| title=Gastritis staging in clinical practice: the OLGA staging system. | journal=Gut | year= 2007 | volume= 56 | issue= 5 | pages= 631-6 | pmid=17142647 | doi=10.1136/gut.2006.106666 | pmc=1942143 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17142647 }} </ref> <ref name="pmid18424244">{{cite journal| author=Rugge M, Correa P, Di Mario F, El-Omar E, Fiocca R, Geboes K et al.| title=OLGA staging for gastritis: a tutorial. | journal=Dig Liver Dis | year= 2008 | volume= 40 | issue= 8 | pages= 650-8 | pmid=18424244 | doi=10.1016/j.dld.2008.02.030 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18424244 }} </ref> | *In clinical practice, Gastritis staging is done using the OLGA (Operative Link on Gastritis Assessment) staging system for reporting gastric histology. Gastritis staging combines the atrophy score which is determined by biopsy and the atrophy topography which is determined by directed biopsy mapping. <ref name="pmid17142647">{{cite journal| author=Rugge M, Meggio A, Pennelli G, Piscioli F, Giacomelli L, De Pretis G et al.| title=Gastritis staging in clinical practice: the OLGA staging system. | journal=Gut | year= 2007 | volume= 56 | issue= 5 | pages= 631-6 | pmid=17142647 | doi=10.1136/gut.2006.106666 | pmc=1942143 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17142647 }} </ref> <ref name="pmid18424244">{{cite journal| author=Rugge M, Correa P, Di Mario F, El-Omar E, Fiocca R, Geboes K et al.| title=OLGA staging for gastritis: a tutorial. | journal=Dig Liver Dis | year= 2008 | volume= 40 | issue= 8 | pages= 650-8 | pmid=18424244 | doi=10.1016/j.dld.2008.02.030 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18424244 }} </ref> | ||
<br/> | <br /> | ||
{| | {| | ||
!colspan="6" style="background:#4479BA; color: #FFFFFF;" align="center" + |'''Gastritis staging in clinical practice: The OLGA staging system''' | ! colspan="6" style="background:#4479BA; color: #FFFFFF;" align="center" + |'''Gastritis staging in clinical practice: The OLGA staging system''' | ||
|- | |- | ||
! | ! colspan="2" rowspan="2" style="background:#4479BA; color: #FFFFFF;" + | '''Atrophy Score''' | ||
! colspan="4" style="background:#4479BA; color: #FFFFFF;" + | '''Corpus''' | ! colspan="4" style="background:#4479BA; color: #FFFFFF;" + | '''Corpus''' | ||
|- | |- | ||
! style="background:#DCDCDC; + | No Atrophy (Score: 0) | ! style="background:#DCDCDC; + " | No Atrophy (Score: 0) | ||
! style="background:#DCDCDC; + | Mild Atrophy (Score: 1) | ! style="background:#DCDCDC; + " | Mild Atrophy (Score: 1) | ||
! style="background:#DCDCDC; + | Moderate Atrophy (Score: 2) | ! style="background:#DCDCDC; + " | Moderate Atrophy (Score: 2) | ||
! style="background:#DCDCDC; + | Severe Atrophy (Score: 3) | ! style="background:#DCDCDC; + " | Severe Atrophy (Score: 3) | ||
|- | |- | ||
!rowspan="4" style="background:#7d7d7d; color: #FFFFFF;" + | | ! rowspan="4" style="background:#7d7d7d; color: #FFFFFF;" + | | ||
A | A | ||
Line 171: | Line 171: | ||
M | M | ||
! style="background:#DCDCDC; + | No Atrophy (Score: 0) (''including incisura angularis'') | ! style="background:#DCDCDC; + " | No Atrophy (Score: 0) (''including incisura angularis'') | ||
| STAGE 0 | | STAGE 0 | ||
| STAGE I | | STAGE I | ||
Line 177: | Line 177: | ||
| STAGE II | | STAGE II | ||
|- | |- | ||
! style="background:#DCDCDC; + | Mild Atrophy (Score: 1) (''including incisura angularis'') | ! style="background:#DCDCDC; + " | Mild Atrophy (Score: 1) (''including incisura angularis'') | ||
| STAGE I | | STAGE I | ||
Line 184: | Line 184: | ||
| STAGE III | | STAGE III | ||
|- | |- | ||
! style="background:#DCDCDC; + | Moderate Atrophy (Score: 2) (''including incisura angularis'') | ! style="background:#DCDCDC; + " | Moderate Atrophy (Score: 2) (''including incisura angularis'') | ||
| STAGE II | | STAGE II | ||
Line 191: | Line 191: | ||
| STAGE IV | | STAGE IV | ||
|- | |- | ||
! style="background:#DCDCDC; + | Severe Atrophy (Score: 3) (''including incisura angularis'') | ! style="background:#DCDCDC; + " | Severe Atrophy (Score: 3) (''including incisura angularis'') | ||
| STAGE III | | STAGE III | ||
Line 202: | Line 202: | ||
{| | {| | ||
!colspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" + |'''Sydney system for grading of Chronic Gastritis''' | ! colspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" + |'''Sydney system for grading of Chronic Gastritis''' | ||
|- | |- | ||
! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" + | Feature | ! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" + | Feature | ||
Line 208: | Line 208: | ||
! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" + | Grading guidelines | ! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" + | Grading guidelines | ||
|- | |- | ||
| style="background:#DCDCDC; + | Chronic inflammation | | style="background:#DCDCDC; + " | Chronic inflammation | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Increased [[lymphocytes]] and [[plasma cells]] in [[lamina propria]] | *Increased [[lymphocytes]] and [[plasma cells]] in [[lamina propria]] | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
* Mild, moderate or severe increase in density | * Mild, moderate or severe increase in density | ||
|- | |- | ||
| style="background:#DCDCDC; + | Activity | | style="background:#DCDCDC; + " | Activity | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*[[Neutrophil|Neutrophilic]] infiltrates of the [[lamina propria]], pits or surface [[epithelium]] | *[[Neutrophil|Neutrophilic]] infiltrates of the [[lamina propria]], pits or surface [[epithelium]] | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
* Mild: less than one-third of pits and surface infiltrated | * Mild: less than one-third of pits and surface infiltrated | ||
* Moderate: one-third to two-thirds | * Moderate: one-third to two-thirds | ||
* Severe: more than two-thirds | * Severe: more than two-thirds | ||
|- | |- | ||
| style="background:#DCDCDC; + | [[Atrophy]] | | style="background:#DCDCDC; + " | [[Atrophy]] | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Loss of specialized glands from either antrum or corpus | *Loss of specialized glands from either antrum or corpus | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
* Mild, moderate, or severe loss | * Mild, moderate, or severe loss | ||
|- | |- | ||
| style="background:#DCDCDC; + | ''[[Helicobacter pylori]]'' | | style="background:#DCDCDC; + " | ''[[Helicobacter pylori]]'' | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*''[[H. pylori]]'' density | *''[[H. pylori]]'' density | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
* Mild colonization: scattered organisms covering less than one-third of the surface | * Mild colonization: scattered organisms covering less than one-third of the surface | ||
* Moderate colonization: intermediate numbers | * Moderate colonization: intermediate numbers | ||
* Severe colonization: large clusters or a continuous layer over two-thirds of surface | * Severe colonization: large clusters or a continuous layer over two-thirds of surface | ||
|- | |- | ||
| style="background:#DCDCDC; + | Intestinal [[Metaplasia]] | | style="background:#DCDCDC; + " | Intestinal [[Metaplasia]] | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
*Intestinal [[metaplasia]] of the epithelium | *Intestinal [[metaplasia]] of the epithelium | ||
| style="background:#F5F5F5; + | | | style="background:#F5F5F5; + " | | ||
* Mild: less than one-third of mucosa involved | * Mild: less than one-third of mucosa involved | ||
* Moderate: one-third to two-thirds | * Moderate: one-third to two-thirds |
Revision as of 13:15, 18 December 2017
Gastritis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Gastritis classification On the Web |
American Roentgen Ray Society Images of Gastritis classification |
Risk calculators and risk factors for Gastritis classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Reddy Kothagadi M.B.B.S[2]}}
Overview
The Updated Sydney System establishes the classification and grading of gastritis which underlines the significance of combining topographical, morphological, and etiological information to help arrive at clinical diagnosis. In clinical practice, Gastritis staging is done using the OLGA (Operative Link on Gastritis Assessment) staging system for reporting gastric histology. Gastritis staging combines the atrophy score which is determined by biopsy and the atrophy topography which is determined by directed biopsy mapping.
Classification
- The Updated Sydney System establishes the classification and grading of gastritis which underlines the significance of combining topographical, morphological, and etiological information to help arrive at clinical diagnosis. [1]
Classification and grading of Gastritis: Updated Sydney System | |||
---|---|---|---|
Type of Gastritis | Etiology | Gastritis synonyms | |
Non-atrophic |
|
| |
Atrophic | Autoimmune |
|
|
Multifocal atrophic |
|
| |
|
| ||
|
| ||
Special forms | Chemical |
|
|
|
| ||
|
| ||
|
| ||
Radiation |
|
||
Lymphocytic |
|
| |
|
| ||
|
|||
|
|||
Noninfectious granulomatous |
|
||
|
|||
|
|||
|
|||
|
| ||
Eosinophilic |
|
| |
|
|||
Other infectious gastritides |
|
| |
|
- In clinical practice, Gastritis staging is done using the OLGA (Operative Link on Gastritis Assessment) staging system for reporting gastric histology. Gastritis staging combines the atrophy score which is determined by biopsy and the atrophy topography which is determined by directed biopsy mapping. [2] [3]
Gastritis staging in clinical practice: The OLGA staging system | |||||
---|---|---|---|---|---|
Atrophy Score | Corpus | ||||
No Atrophy (Score: 0) | Mild Atrophy (Score: 1) | Moderate Atrophy (Score: 2) | Severe Atrophy (Score: 3) | ||
A N T R U M |
No Atrophy (Score: 0) (including incisura angularis) | STAGE 0 | STAGE I | STAGE II | STAGE II |
Mild Atrophy (Score: 1) (including incisura angularis) | STAGE I | STAGE I | STAGE II | STAGE III | |
Moderate Atrophy (Score: 2) (including incisura angularis) | STAGE II | STAGE II | STAGE III | STAGE IV | |
Severe Atrophy (Score: 3) (including incisura angularis) | STAGE III | STAGE III | STAGE IV | STAGE IV |
Sydney system for grading of chronic gastritis[1]
Sydney system for grading of Chronic Gastritis | ||
---|---|---|
Feature | Definition | Grading guidelines |
Chronic inflammation |
|
|
Activity |
|
|
Atrophy |
|
|
Helicobacter pylori |
|
|
Intestinal Metaplasia |
|
|
References
- ↑ 1.0 1.1 Dixon MF, Genta RM, Yardley JH, Correa P (1996). "Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994". Am J Surg Pathol. 20 (10): 1161–81. PMID 8827022.
- ↑ Rugge M, Meggio A, Pennelli G, Piscioli F, Giacomelli L, De Pretis G; et al. (2007). "Gastritis staging in clinical practice: the OLGA staging system". Gut. 56 (5): 631–6. doi:10.1136/gut.2006.106666. PMC 1942143. PMID 17142647.
- ↑ Rugge M, Correa P, Di Mario F, El-Omar E, Fiocca R, Geboes K; et al. (2008). "OLGA staging for gastritis: a tutorial". Dig Liver Dis. 40 (8): 650–8. doi:10.1016/j.dld.2008.02.030. PMID 18424244.